Sunday, May 14, 2017, Boston, MA — 6:00 PM – 8:00 PM (Eastern Time)

What Urologists Want to Know: Addressing Current Questions and Controversies Regarding the Role of Immune Checkpoint Inhibitors in the Management of Bladder Cancer

Location:
The Westin Boston Waterfront
425 Summer Street
Boston, MA 02210
Hotel Phone: (617) 532-4600

Time:
5:30 PM – 6:00 PM (Eastern Time) — Registration and Dinner Buffet
6:00 PM – 8:00 PM (Eastern Time) — Educational Meeting

Meeting Room:
Harbor Ballroom (Conference Level)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
 
Faculty:
Sia Daneshmand, MD
Associate Professor of Urology (Clinical Scholar)
Director of Urologic Oncology
Director of Clinical Research
Urologic Oncology Fellowship Director
USC/Norris Comprehensive Cancer Center
Institute of Urology
Los Angeles, California

Charles G Drake, MD, PhD
Professor of Medicine
Co-Director, Cancer Immunotherapy Programs
Columbia University Medical Center
New York, New York

Elizabeth R Plimack, MD, MS
Director, Genitourinary Clinical Research
Associate Professor, Department of Hematology/Oncology
Fox Chase Cancer Center, Temple Health
Philadelphia, Pennsylvania


Jonathan E Rosenberg, MD
Associate Attending Physician
Section Head, Non-Prostate Genitourinary Cancers
Genitourinary Oncology Service
Enno Ercklentz Endowed Chair
Memorial Sloan Kettering Cancer Center
New York, New York

Robert S Svatek, MD
Associate Professor
Department of Urology
UT Health Science Center
San Antonio, Texas

Moderator:
Neil Love, MD
Research To Practice
Miami, Florida

MODULE 1: Current Urothelial Bladder Cancer (UBC) Management Approaches and the Integration of Immune Checkpoint Inhibitors — Dr Daneshmand

Presentation and Discussion Topics

  • Clinical controversies in the use of adjuvant versus neoadjuvant chemotherapy for patients with muscle-invasive UBC; potential role, if any, for perioperative systemic treatment
  • Ongoing trials and existing data on the use of neoadjuvant systemic therapy in patients who are not eligible for cisplatin
  • Identification of patients with potentially curable UBC who should undergo cystectomy; optimal monitoring and follow-up
  • Common sites of recurrence and optimal integration of salvage therapy into the bladder cancer management algorithm
  • Role of the urologist in timely referral to a medical oncologist for consideration of treatment with an anti-PD-1/PD-L1 antibody

MODULE 2: Principles and Precepts of Cancer Immunotherapy; Practical Considerations with the Use of Immune Checkpoint Inhibitors — Dr Drake

Presentation and Discussion Topics

  • Major approaches to genitourinary cancer immunotherapy and how they are potentially interrelated (eg, targeting innate versus adaptive immune systems, targeting and/or using dendritic cells/T cells, role of the tumor microenvironment, immune checkpoint blockade)
  • Biologic rationale for the evaluation of immune checkpoint inhibitors in UBC; mechanistic similarities and differences among approved and investigational anti-PD-1/PD-L1 antibodies
  • PD-L1 staining in tumor and immune cells and correlation, if any, with clinical response to immune checkpoint inhibitors for UBC
  • Relevance, if any, of other clinical or biologic factors (eg, stage of disease, smoking history, “mutational” load) to potential response to immune checkpoint inhibition in UBC
  • Assessment of clinical response in trials of immune checkpoint inhibitors in UBC

MODULE 3: Overview of and Current Indications for the Use of Immune Checkpoint Inhibitors in UBC — Dr Rosenberg

Presentation and Discussion Topics

  • Available research data with and FDA indications for the use of atezolizumab and nivolumab for patients with advanced UBC
  • Overall survival benefit observed in the Phase III KEYNOTE-045 trial comparing pembrolizumab to paclitaxel, docetaxel or vinflunine for patients with recurrent or progressive advanced UBC; potential role of pembrolizumab in clinical practice
  • FDA breakthrough therapy designation for durvalumab in the treatment of UBC; implications for clinical development timelines
  • Current clinical role of anti-PD-1/PD-L1 therapy as first-line treatment for patients with metastatic UBC

MODULE 4: Incidence and Management of Unique Toxicities Associated with Checkpoint Inhibitors; Autoimmune Contraindications to Treatment — Dr Plimack

Presentation and Discussion Topics

  • Recognition and time course of immune-mediated toxicities with the use of anti-PD-1/PD-L1 antibodies in patients with UBC; cumulative effects, if any, of prolonged exposure
  • Specific organ toxicities associated with anti-PD-1/PD-L1 antibodies
  • Management of common immune toxicities and role of corticosteroids and other immune suppressants
  • Autoimmune contraindications to treatment with immunotherapy
  • Clinical experience with the use of checkpoint inhibitors in patients with Crohn’s disease, psoriasis, multiple sclerosis, et cetera

MODULE 5: Ongoing Clinical Research with Immune Checkpoint Inhibitors in UBC — Dr Svatek

Presentation and Discussion Topics

  • Rationale, design and entry criteria for active clinical trials examining the use of anti-PD-1/PD-L1 antibodies and other immunotherapeutic approaches for high-risk non-muscle-invasive UBC in patients unresponsive to or concurrently receiving bacillus Calmette-Guerin therapy
  • Potential role of anti-PD-1/PD-L1 antibodies as neoadjuvant systemic therapy for patients with muscle-invasive UBC
  • Ongoing trials of adjuvant checkpoint inhibition in patients with “high-risk” invasive disease
  • Phase I/II CheckMate 032 trial results with nivolumab/ipilimumab for patients with UBC previously treated with platinum-based therapy; ongoing evaluation of anti-PD-1/PD-L1 and anti-CTLA-4 combinations
  • Other novel combination approaches with anti-PD-1/PD-L1 antibodies and immunotherapeutic, cytotoxic or targeted agents in UBC

Target Audience:
This activity has been designed to meet the educational needs of medical oncologists, urologists and other allied healthcare professionals involved in the treatment of bladder cancer.

Learning Objectives and Goals:
At the conclusion of this activity, participants should be able to:

  • Develop a basic understanding of the human immune response, and identify the underlying mechanisms by which various tumor types evade this process to proliferate and grow.
  • Analyze the biologic basis for the development of immune checkpoint inhibitors designed to boost an individual’s immune response to combat the development of urothelial bladder carcinoma (UBC).
  • Compare and contrast the mechanisms of action, efficacy and safety of approved and investigational immune checkpoint inhibitors for the treatment of advanced UBC to determine the current and/or potential utility of each in clinical practice.
  • Recognize immune-related adverse events and other common side effects associated with approved and developmental checkpoint inhibitors used in the management of UBC, and offer supportive management strategies to minimize and/or manage these side effects.
  • Review ongoing research to assist in the identification of biomarkers, tumor characteristics and other clinical features that are indicative of response to immune checkpoint inhibitors in patients with UBC.
  • Describe ongoing clinical trials evaluating novel applications of immune checkpoint inhibitors alone (eg, adjuvant therapy, first-line therapy) or in combination with other systemic approaches (eg, anti-PD-1/PD-L1 + BCG, anti-PD-1/PD-L1 + anti-CTLA-4 antibodies, anti-PD-1/ PD-L1 + chemotherapy), and counsel appropriately selected patients with UBC about trial availability and potential participation.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters:
This activity is supported by educational grants from grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company and Merck.

The Westin Boston Waterfront
425 Summer Street
Boston, MA 02210
Hotel Phone: (617) 532-4600

Meeting Room:
Harbor Ballroom (Conference Level)

Directions:
The Westin Boston Waterfront hotel is connected to the Boston Convention and Exhibition Center.

 

This activity has been designed to meet the educational needs of medical oncologists, urologists and other allied healthcare professionals involved in the treatment of bladder cancer.

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice

I am a practicing physician, fellow or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/ industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in with our on-site registration desk at least 30 minutes prior to the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CME programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.